News & Media

Recent updates from Arcutis.

June 29, 2026 Featured

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2

October 6, 2025 Featured

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

May 22, 2025 Featured

Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

July 8, 2026

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

July 2, 2026

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 30, 2026

Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications

June 5, 2026

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2026

New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology

May 26, 2026

Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference

May 8, 2026

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 6, 2026

Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

April 27, 2026

Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months

April 22, 2026

Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

April 15, 2026

Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

Media Resources

Corporate Fact Sheet

Skin Insights Survey: Steroid Perceptions Among Adults & Parents of Children with Chronic Inflammatory Skin Diseases

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

Madison Joseph

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download